JP2020502219A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020502219A5 JP2020502219A5 JP2019533586A JP2019533586A JP2020502219A5 JP 2020502219 A5 JP2020502219 A5 JP 2020502219A5 JP 2019533586 A JP2019533586 A JP 2019533586A JP 2019533586 A JP2019533586 A JP 2019533586A JP 2020502219 A5 JP2020502219 A5 JP 2020502219A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- set forth
- sequence set
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000037396 body weight Effects 0.000 claims description 22
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 229920001184 polypeptide Polymers 0.000 claims description 11
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 11
- 206010031243 Osteogenesis imperfecta Diseases 0.000 claims description 7
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 claims description 6
- 229940122361 Bisphosphonate Drugs 0.000 claims description 3
- 229940123613 Calcium receptor antagonist Drugs 0.000 claims description 3
- 102000013830 Calcium-Sensing Receptors Human genes 0.000 claims description 3
- 108010050543 Calcium-Sensing Receptors Proteins 0.000 claims description 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 3
- 239000003263 anabolic agent Substances 0.000 claims description 3
- 229940070021 anabolic steroids Drugs 0.000 claims description 3
- 150000004663 bisphosphonates Chemical class 0.000 claims description 3
- VDHAWDNDOKGFTD-MRXNPFEDSA-N cinacalcet Chemical compound N([C@H](C)C=1C2=CC=CC=C2C=CC=1)CCCC1=CC=CC(C(F)(F)F)=C1 VDHAWDNDOKGFTD-MRXNPFEDSA-N 0.000 claims description 3
- 229960003315 cinacalcet Drugs 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 3
- 229910052746 lanthanum Inorganic materials 0.000 claims description 3
- FZLIPJUXYLNCLC-UHFFFAOYSA-N lanthanum atom Chemical compound [La] FZLIPJUXYLNCLC-UHFFFAOYSA-N 0.000 claims description 3
- 239000000199 parathyroid hormone Substances 0.000 claims description 3
- 239000000018 receptor agonist Substances 0.000 claims description 3
- 229940044601 receptor agonist Drugs 0.000 claims description 3
- 235000013024 sodium fluoride Nutrition 0.000 claims description 3
- 239000011775 sodium fluoride Substances 0.000 claims description 3
- 159000000008 strontium salts Chemical class 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- 101150008656 COL1A1 gene Proteins 0.000 claims description 2
- 101150072801 COL1A2 gene Proteins 0.000 claims description 2
- 102100033601 Collagen alpha-1(I) chain Human genes 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims description 2
- 238000011269 treatment regimen Methods 0.000 claims description 2
- 230000003442 weekly effect Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 18
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 238000011282 treatment Methods 0.000 claims 2
- 150000001413 amino acids Chemical group 0.000 description 45
- 238000000034 method Methods 0.000 description 37
- 239000002552 dosage form Substances 0.000 description 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229960003589 arginine hydrochloride Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 229960000443 hydrochloric acid Drugs 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021200994A JP2022046529A (ja) | 2016-12-21 | 2021-12-10 | 骨形成不全症の処置における抗スクレロスチン抗体の使用 |
| JP2024179475A JP2025020150A (ja) | 2016-12-21 | 2024-10-11 | 骨形成不全症の処置における抗スクレロスチン抗体の使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662437353P | 2016-12-21 | 2016-12-21 | |
| US62/437,353 | 2016-12-21 | ||
| PCT/GB2017/053850 WO2018115880A1 (en) | 2016-12-21 | 2017-12-21 | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021200994A Division JP2022046529A (ja) | 2016-12-21 | 2021-12-10 | 骨形成不全症の処置における抗スクレロスチン抗体の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020502219A JP2020502219A (ja) | 2020-01-23 |
| JP2020502219A5 true JP2020502219A5 (enExample) | 2021-02-04 |
| JP7050335B2 JP7050335B2 (ja) | 2022-04-08 |
Family
ID=60915566
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019533586A Active JP7050335B2 (ja) | 2016-12-21 | 2017-12-21 | 骨形成不全症の処置における抗スクレロスチン抗体の使用 |
| JP2021200994A Pending JP2022046529A (ja) | 2016-12-21 | 2021-12-10 | 骨形成不全症の処置における抗スクレロスチン抗体の使用 |
| JP2024179475A Pending JP2025020150A (ja) | 2016-12-21 | 2024-10-11 | 骨形成不全症の処置における抗スクレロスチン抗体の使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021200994A Pending JP2022046529A (ja) | 2016-12-21 | 2021-12-10 | 骨形成不全症の処置における抗スクレロスチン抗体の使用 |
| JP2024179475A Pending JP2025020150A (ja) | 2016-12-21 | 2024-10-11 | 骨形成不全症の処置における抗スクレロスチン抗体の使用 |
Country Status (23)
| Country | Link |
|---|---|
| US (5) | US20200179509A1 (enExample) |
| EP (2) | EP3868780A1 (enExample) |
| JP (3) | JP7050335B2 (enExample) |
| KR (3) | KR20190096409A (enExample) |
| CN (2) | CN117442720A (enExample) |
| AU (1) | AU2017381433B2 (enExample) |
| BR (1) | BR112019012731A2 (enExample) |
| CA (1) | CA3047221A1 (enExample) |
| CL (1) | CL2019001749A1 (enExample) |
| CY (1) | CY1124238T1 (enExample) |
| DK (1) | DK3478719T6 (enExample) |
| ES (1) | ES2862922T7 (enExample) |
| FI (1) | FI3478719T6 (enExample) |
| HR (1) | HRP20210207T4 (enExample) |
| HU (1) | HUE053436T2 (enExample) |
| IL (1) | IL267430B1 (enExample) |
| LT (1) | LT3478719T (enExample) |
| MX (1) | MX2019007161A (enExample) |
| NZ (1) | NZ754676A (enExample) |
| PL (1) | PL3478719T6 (enExample) |
| PT (1) | PT3478719T (enExample) |
| SI (1) | SI3478719T2 (enExample) |
| WO (1) | WO2018115880A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020502218A (ja) | 2016-12-21 | 2020-01-23 | メレオ バイオファーマ ３ リミテッド | 骨形成不全症の処置における抗スクレロスチン抗体の使用 |
| TWI795381B (zh) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為ｍａｌｔ１抑制劑之吡唑衍生物 |
| WO2018115880A1 (en) * | 2016-12-21 | 2018-06-28 | Mereo Biopharma 3 Limited | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
| CN119241705A (zh) | 2018-03-30 | 2025-01-03 | 安姆根有限公司 | C末端抗体变体 |
| MX2020013899A (es) | 2018-06-18 | 2021-05-27 | Janssen Pharmaceutica Nv | Derivados de pirazol como inhibidores de malt1. |
| BR112021019799A2 (pt) | 2019-04-11 | 2021-12-07 | Janssen Pharmaceutica Nv | Derivados contendo anéis de piridina como inibidores de malt1 |
| KR102472582B1 (ko) * | 2020-08-20 | 2022-11-30 | 한림대학교 산학협력단 | 인공관절 마모편에 의한 활막염과 골용해의 진단 및 치료 방법 |
| WO2023056355A2 (en) * | 2021-09-30 | 2023-04-06 | Mereo Biopharma 3 Limited | Methods of using anti-sclerostin antibodies in treatment of osteogenesis imperfecta |
| WO2025212547A1 (en) * | 2024-04-05 | 2025-10-09 | Amgen Inc. | Methods of treating osteogenesis imperfecta |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
| US6395511B1 (en) | 1998-11-27 | 2002-05-28 | Darwin Discovery, Ltd. | Nucleic acids encoding a novel family of TGF-β binding proteins from humans |
| EA015166B1 (ru) | 2003-06-16 | 2011-06-30 | Ю-Си-Би Мэньюфэкчуринг, Инк. | Иммуногенные пептиды склеростина (sost), индуцирующие образование специфических антител |
| US7592429B2 (en) * | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| WO2008061013A2 (en) | 2006-11-10 | 2008-05-22 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
| RS53157B (sr) * | 2007-03-20 | 2014-06-30 | Eli Lilly And Company | Antitela na sklerostin |
| CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
| AR068767A1 (es) | 2007-10-12 | 2009-12-02 | Novartis Ag | Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina |
| WO2010100200A2 (en) * | 2009-03-05 | 2010-09-10 | Novartis Ag | Lyophilised antibody formulation |
| AU2011239935A1 (en) * | 2010-04-16 | 2012-11-08 | Novartis Ag | Methods and compositions for improving implant osseointegration |
| RU2620071C2 (ru) * | 2010-11-17 | 2017-05-22 | Чугаи Сеияку Кабушики Каиша | Мультиспецифическая связывающая антиген молекула, которая обладает альтернативной функцией к функции фактора свертывания крови viii |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| MA41142A (fr) * | 2014-12-12 | 2017-10-17 | Amgen Inc | Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement |
| WO2018115880A1 (en) * | 2016-12-21 | 2018-06-28 | Mereo Biopharma 3 Limited | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
| JP2020502218A (ja) * | 2016-12-21 | 2020-01-23 | メレオ バイオファーマ ３ リミテッド | 骨形成不全症の処置における抗スクレロスチン抗体の使用 |
-
2017
- 2017-12-21 WO PCT/GB2017/053850 patent/WO2018115880A1/en not_active Ceased
- 2017-12-21 EP EP21152251.1A patent/EP3868780A1/en active Pending
- 2017-12-21 IL IL267430A patent/IL267430B1/en unknown
- 2017-12-21 KR KR1020197021162A patent/KR20190096409A/ko not_active Ceased
- 2017-12-21 CN CN202311429543.0A patent/CN117442720A/zh active Pending
- 2017-12-21 PT PT178231908T patent/PT3478719T/pt unknown
- 2017-12-21 EP EP17823190.8A patent/EP3478719B3/en active Active
- 2017-12-21 KR KR1020247023410A patent/KR20240113615A/ko not_active Ceased
- 2017-12-21 NZ NZ754676A patent/NZ754676A/en unknown
- 2017-12-21 PL PL17823190.8T patent/PL3478719T6/pl unknown
- 2017-12-21 US US16/469,915 patent/US20200179509A1/en not_active Abandoned
- 2017-12-21 HU HUE17823190A patent/HUE053436T2/hu unknown
- 2017-12-21 LT LTEP17823190.8T patent/LT3478719T/lt unknown
- 2017-12-21 DK DK17823190.8T patent/DK3478719T6/da active
- 2017-12-21 FI FIEP17823190.8T patent/FI3478719T6/fi active
- 2017-12-21 BR BR112019012731-3A patent/BR112019012731A2/pt unknown
- 2017-12-21 AU AU2017381433A patent/AU2017381433B2/en active Active
- 2017-12-21 MX MX2019007161A patent/MX2019007161A/es unknown
- 2017-12-21 CA CA3047221A patent/CA3047221A1/en active Pending
- 2017-12-21 SI SI201730627T patent/SI3478719T2/sl unknown
- 2017-12-21 HR HRP20210207TT patent/HRP20210207T4/hr unknown
- 2017-12-21 ES ES17823190T patent/ES2862922T7/es active Active
- 2017-12-21 JP JP2019533586A patent/JP7050335B2/ja active Active
- 2017-12-21 KR KR1020227011791A patent/KR20220051269A/ko not_active Ceased
- 2017-12-21 CN CN201780087087.2A patent/CN110325548B/zh active Active
-
2019
- 2019-06-21 CL CL2019001749A patent/CL2019001749A1/es unknown
-
2020
- 2020-01-02 US US16/733,144 patent/US20200123242A1/en not_active Abandoned
- 2020-12-30 US US17/138,691 patent/US20210253684A1/en not_active Abandoned
-
2021
- 2021-04-02 CY CY20211100286T patent/CY1124238T1/el unknown
- 2021-12-10 JP JP2021200994A patent/JP2022046529A/ja active Pending
-
2023
- 2023-04-07 US US18/297,280 patent/US20230365669A1/en not_active Abandoned
-
2024
- 2024-05-20 US US18/669,337 patent/US20240400666A1/en active Pending
- 2024-10-11 JP JP2024179475A patent/JP2025020150A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020502219A5 (enExample) | ||
| JP2014114288A5 (enExample) | ||
| JP2017160208A5 (enExample) | ||
| FI3478719T6 (fi) | Anti-sklerostiini-vasta-aineiden käyttö synnynnäisen luutumisvajauden hoitamisessa | |
| JP2016528247A5 (enExample) | ||
| CN114286828A (zh) | 针对靶向b细胞成熟抗原的多特异性抗体的给药方案和组合疗法 | |
| JP2016537340A5 (enExample) | ||
| CN107029234A (zh) | 利用il‑17拮抗剂治疗牛皮癣的方法 | |
| JP2016535020A5 (enExample) | ||
| JP2017500018A5 (enExample) | ||
| JP2021193121A (ja) | Ｉｌ−１７アンタゴニストを使用して汎発性膿疱性乾癬（ｇｐｐ）を処置する方法 | |
| JP2018515493A5 (enExample) | ||
| JP2015525798A5 (enExample) | ||
| JP2017160178A5 (enExample) | ||
| JP2019532970A5 (enExample) | ||
| JP2020502218A5 (enExample) | ||
| KR20170045240A (ko) | 건선성 관절염 환자에서 구조적 손상의 진행을 억제하기 위한 il-17 길항제의 용도 | |
| JP2018512402A5 (enExample) | ||
| JP2019519584A5 (enExample) | ||
| JP2020523384A5 (enExample) | ||
| EP4373525A1 (en) | Cancer treatment combinations | |
| JP2017524675A5 (enExample) | ||
| JP2021506817A5 (enExample) | ||
| JP2020505350A5 (enExample) | ||
| JP2017515843A5 (enExample) |